There has been a lot of discussion about the high price of Gilead's Hepatitis C drug Sovaldi, and a variety of strong opinions expressed. But are agencies around the world asking the right ...

Gilead Sciences generates stellar profit margins with its HIV and hepatitis C virus, or HCV, portfolio, which requires only a small salesforce and inexpensive manufacturing. We think its portfolio ...

In the latest market close, Gilead Sciences (GILD) reached $115.99, with a +1.47% movement compared to the previous day. This move outpaced the S&P 500's daily loss of 1.76%. Meanwhile, the Dow ...

Gilead Sciences sets aside $200 million for a potential settlement over its HIV drug promotional speaker program amid federal investigation.

Gilead Sciences specializes in developing antiviral drugs that treat HIV, hepatitis B, hepatitis C, and influenza. Recently, it has focused on expanding its oncology portfolio. The company views ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Gilead Sciences Inc. GILD stock surged to a ... its $84,000 treatment for hepatitis C (hep C). The 12-week treatment was the world’s first and only cure for hep C, but the cost made it ...

Gilead Sciences (GILD ... Over the past month, shares of this HIV and hepatitis C drugmaker have returned +15.6%, compared to the Zacks S&P 500 composite's -2.2% change. During this period ...